Five new research posts went live on labisan.shop today. They came out of two technical research dumps we worked through this week: a German-language pharmacology file on Annona muricata acetogenins, NOX and HIF-1α cell-mechanism research, and the Caparros-Lefebvre Caribbean safety signal; and a separate file with the latest global HSV-1 and HSV-2 epidemiology stats from HNO and the Springer chapter literature. Three of the new posts deepen the Graviola Pharmacology Deep Dive series. Two open the HSV Education series with proper epidemiology depth. Below is the index, the reading order, and the question each post answers.
If you want the short version: the science says whole-extract pharmacology beats single-isolate marketing, the prostate cell-line mechanism research is real and worth understanding as research-not-treatment, the Caribbean Parkinson signal is the safety story everyone glosses over, HSV-1 is the modal condition of the adult population, and the cross-site recurrence asymmetry changes how genital HSV-1 should actually be explained. The dual Labisan Protective Lip Balm plus Labisan Graviola Capsules system is the daily protocol all of this maps to.
The Three Graviola Pharmacology Posts
1. The honest acetogenin answer
Is There a Specific Anti-Herpes Acetogenin in Graviola? An Honest Pharmacology Answer.
More than 500 acetogenins have been isolated from Annona muricata. None has been cleanly identified as the anti-herpes molecule. The literature points to whole-extract activity, not isolate activity, which is why Labisan Graviola Capsules are formulated as a 22:1 fruit water extract that preserves the full chemical matrix rather than chasing an isolate the science has not actually named.
2. The cell-mechanism explainer
NOX, HIF-1α and Graviola: Gas Pedal, War Mode, Brake Pedal — A Pharmacology Explainer
The clearest piece of Annona muricata pharmacology research to date is the NOX and HIF-1α work in prostate cancer cell lines. NOX is the gas pedal that produces tumour-driving oxidative stress. HIF-1α is the war-mode emergency manager that switches on the survival programme under hypoxia. Graviola fruit pulp extract brakes both, with selectivity for cancer cells over normal cells. Explicit framing throughout: research, not treatment.
3. The safety architecture post
Annonacin and the Caribbean Parkinson Signal: Why the Labisan Safety Architecture Matters
The 1999 Caparros-Lefebvre Guadeloupe atypical-parkinsonism cluster is the most-glossed-over piece of graviola safety literature. This post puts it in dose context (the Caribbean exposure was leaf-tea and bark over years, not a capsule a day) and walks through the three engineering choices that put Labisan Graviola Capsules two orders of magnitude below the chronic-exposure zone: fruit pulp not leaf, fixed three-capsule daily cap, one-year-on one-year-off cycling.
The Two HSV Education Posts
4. HSV-1 by the numbers
HSV-1 By the Numbers: 85 Percent of the World, 40 Percent by Age 12, and What That Means for You
The global epidemiology in one place. 85 percent of the world adult population is HSV-1 seropositive. Forty percent of children in industrial countries by age 12. HSV-2 at 10 to 20 percent. Rare serious complications named. The practical implication is the part most coverage misses: HSV-1 is the modal condition, the daily-protocol toolkit is mature, and Labisan Protective Lip Balm with Labisan Graviola Capsules is the dual layer the modal carrier actually needs.
5. The cross-site recurrence asymmetry
When HSV-1 Goes Genital and HSV-2 Goes Oral: The Cross-Site Crossover That Changes Everything
HSV-1 now causes 40 to 50 percent of new genital herpes infections in young adults. HSV-2 occasionally lands oral. The non-obvious story is the recurrence pattern: HSV-1 at its non-preferred genital site recurs less than once a year and often never returns after the primary outbreak, while HSV-1 at the lip recurs four to six times a year. The site-virus pairing predicts the recurrence rate more reliably than the virus type alone, and almost no consumer-facing herpes content gets this right.
How to Read These
If graviola pharmacology is what brought you here, start with post 1 then read posts 2 and 3 in order, then pick up the rest of the Graviola Pharmacology Deep Dive series. If HSV epidemiology and biology is your angle, start with post 4 then post 5, then continue in the HSV Education series. The full Labisan Research Series index covers everything across five curated reading lists.
The daily-protocol system all of this maps to
Labisan Protective Lip Balm + Labisan Graviola Capsules
Lip Balm: $24.99 single | 3x $59.99 | 5x $89.99 — Graviola: $44.99 single | 3x $119.97 | 5x $179.95
Made in Austria. Free shipping on orders over $49. 30 day money back guarantee on both products.
Shop Lip Balm Shop Graviola CapsulesBottom Line
Five posts. Two research sources. Three on graviola pharmacology, two on HSV epidemiology. All five live now, all five linked above, all five integrated into the two pillar series. The full reading lists sit at /series/graviola-pharmacology and /series/hsv-education. The products are at Labisan Protective Lip Balm and Labisan Graviola Capsules. The next research drop publishes when the next dump lands.
